Different assessment tools to detect sarcopenia in patients with Parkinson's disease.
Parkinson's disease
prevalence
sarcopenia
screening tool
sensitivity
specificity
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
08
2022
accepted:
07
11
2022
entrez:
15
12
2022
pubmed:
16
12
2022
medline:
16
12
2022
Statut:
epublish
Résumé
Sarcopenia and Parkinson's disease are closely related diseases of the elderly population leading to progressive disability and nursing-dependent care. The aim of this study was to estimate the prevalence of sarcopenia in PD patients with three different approaches: (1) the screening tool SARC-F, (2) EWGSOP-1 criteria, and (3) EWGSOP-2 criteria. Moreover, we aimed to evaluate the diagnostic accuracy of the screening tool SARC-F to detect sarcopenia according to the updated EWGSOP-2 criteria. Eighty-one patients with Parkinson's disease aged 65 years and above were interviewed in a cross-sectional study at a tertiary referral center. All patients were screened with the SARC-F questionnaire and were evaluated for motor and non-motor symptoms, exercise, quality of life, and frailty. Muscle mass was assessed with bioelectrical impedance analysis, handgrip strength with a dynamometer, and gait speed was assessed with the 8-m walk test. EWGSOP-2 criteria were considered the gold standard to diagnose sarcopenia in our study. Eighty-one patients were evaluated (mean age: 73.82; SD 5.30). The prevalence of sarcopenia was 28.4% according to the EWGSOP-2 criteria. The concordance between EWGSOP-2 and EWGSOP-1 was poor (weighted kappa of 0.361[95% 0.164-0.557]). The sensitivity of the SARC-F screening test for detecting sarcopenia was 60.9%. The corresponding AUC in the ROC curve analysis showed 0.598 (0.462, 0.734 CI). The item assessing strength was found to have the highest sensitivity (69.6%). Sarcopenia prevalence in patients with PD in Tirol, Austria is higher with EWGSOP-1 criteria compared to EWGSOP-2 criteria. The sensitivity and specificity of the SARC-F scale to detect sarcopenia in this population are poor.
Identifiants
pubmed: 36518192
doi: 10.3389/fneur.2022.1014102
pmc: PMC9742236
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1014102Informations de copyright
Copyright © 2022 Valent, Peball, Krismer, Lanbach, Zemann, Horlings, Poewe and Seppi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cachexia Sarcopenia Muscle. 2016 May;7(2):136-43
pubmed: 27493867
Neurosci Lett. 2010 Jan 1;468(1):56-8
pubmed: 19857551
Neurol Sci. 2018 Aug;39(8):1415-1421
pubmed: 29752635
Exp Gerontol. 2021 Feb;144:111183
pubmed: 33279661
J Aging Res. 2013;2013:791679
pubmed: 23577254
Gerontology. 2020;66(4):409-415
pubmed: 32088717
J Diabetes Metab Disord. 2020 May 29;19(2):727-734
pubmed: 33520799
J Am Med Dir Assoc. 2016 Dec 1;17(12):1129-1135
pubmed: 27666334
Arch Gerontol Geriatr. 2020 Sep - Oct;90:104125
pubmed: 32534364
Neurol Sci. 2020 Feb;41(2):313-320
pubmed: 31583555
Age Ageing. 2014 Nov;43(6):748-59
pubmed: 25241753
J Nutr Health Aging. 2020;24(7):783-790
pubmed: 32744576
J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):28-36
pubmed: 27066316
Front Endocrinol (Lausanne). 2014 Dec 18;5:217
pubmed: 25566189
Behav Neurol. 2011;24(3):219-28
pubmed: 21876261
J Nutr Health Aging. 2021;25(6):757-761
pubmed: 34179930
Geriatr Gerontol Int. 2016 Jan;16(1):5-20
pubmed: 26016893
In Vivo. 2021 Nov-Dec;35(6):3001-3009
pubmed: 34697131
Gerontology. 2017;63(5):411-416
pubmed: 28675898
Clin Nutr. 2020 Jul;39(7):2301-2310
pubmed: 31732287
Arch Gerontol Geriatr. 2020 Jul - Aug;89:104081
pubmed: 32485520
J Gerontol A Biol Sci Med Sci. 2018 Aug 10;73(9):1199-1204
pubmed: 29300839
Front Neurol. 2021 Mar 05;12:598035
pubmed: 33746871
Clin Nutr. 2015 Aug;34(4):667-73
pubmed: 25103151
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Clin Nutr ESPEN. 2020 Jun;37:80-86
pubmed: 32359760
J Clin Med. 2020 Jan 16;9(1):
pubmed: 31963202
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
J Am Med Dir Assoc. 2016 Dec 1;17(12):1136-1141
pubmed: 27650212
J Am Med Dir Assoc. 2019 Sep;20(9):1182-1183
pubmed: 31455509
Exp Gerontol. 2020 Apr;132:110835
pubmed: 31954325
Aging Clin Exp Res. 2022 Mar;34(3):505-514
pubmed: 34398438
J Nutr Health Aging. 2018;22(9):1034-1038
pubmed: 30379299
J Am Med Dir Assoc. 2019 Mar;20(3):384-385
pubmed: 30661861
Sci Rep. 2019 Nov 27;9(1):17636
pubmed: 31776354
J Am Med Dir Assoc. 2013 Aug;14(8):531-2
pubmed: 23810110
J Am Med Dir Assoc. 2014 Sep;15(9):630-4
pubmed: 24947762
Eur J Neurosci. 2006 Sep;24(6):1815-20
pubmed: 17004944
Gerontology. 2022;68(8):869-876
pubmed: 34592734
J Nutr Health Aging. 2020;24(10):1053-1060
pubmed: 33244560
Front Aging Neurosci. 2017 Mar 07;9:53
pubmed: 28326036
Gerontology. 2019;65(3):216-228
pubmed: 30199864
Exp Gerontol. 2020 Feb;130:110798
pubmed: 31816424
J Am Med Dir Assoc. 2018 Jun;19(6):523-527
pubmed: 29396191
J Am Med Dir Assoc. 2019 Mar;20(3):382-383.e1
pubmed: 30661862
BMC Geriatr. 2021 Oct 26;21(1):600
pubmed: 34702174
Parkinsonism Relat Disord. 2002 Jan;8(3):161-4
pubmed: 12039425
J Am Med Dir Assoc. 2016 Jul 1;17(7):640-6
pubmed: 27143236
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):576-83
pubmed: 24737560
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):86-99
pubmed: 34816624